In the CLEAR SYNERGY trial, routine spironolactone after myocardial infarction did not reduce cardiovascular AEs in patients ...

Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...

The literature increasingly acknowledges the role of inflammation in the development of atherosclerosis. Colchicine, a potent anti-inflammatory drug commonly used to treat gout and pericarditis, is ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a ...

New research found that the medication spironolactone, often prescribed for hypertension (high blood pressure), may reduce the risk of heart failure in people recovering from a heart attack.

The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not ...

The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not ...

If you're looking for nonsurgical osteoarthritis (OA) treatments with fewer side effects than ordinary pain relievers, two ...

Washington Convention Center in Washington, D.C. on November 14 – 19, 2024. Title: Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution ...